No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction

Sang Yup Lim

doi:10.4068/cmj.2016.52.1.38

Journal List > Chonnam Med J > v.52(1) > 1018001

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lim: No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction

Review Article

Chonnam Medical Journal 2016; 52(1): 38-44.

Published online: 19 January 2016

DOI: https://doi.org/10.4068/cmj.2016.52.1.38

No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction

Sang Yup Lim

Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.

Corresponding Author: Sang Yup Lim. Department of Internal Medicine, Korea University Ansan Hospital, 516 Gojan-dong, Danwon-gu, Ansan 15355, Korea. TEL: +82-31-412-6755, FAX: +82-31-412-5594, vnlover@hanmail.net

Received 30 November 2015 Revised 29 December 2015 Accepted 3 January 2016

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Recently, percutaneous coronary intervention has been the treatment of choice in most acute myocardial infarction cases. Although the results of percutaneous coronary interventions have ben good, the no-reflow phenomenon and distal embolization of intracoronary thrombus are still major problems even after successful interventions. In this article, we will briefly review the deleterious effects of no-reflow and distal embolization of intracoronary thrombus during percutaneous coronary interventions. The current trials focused on the prevention and treatment of the no-reflow phenomenon and intracoronary thrombus.

Keywords: Myocardial infarction, No-Reflow phenomenon, Thrombus, Percutaneous coronary intervention

INTRODUCTION

Acute myocardial infarction (AMI) is one of the most common causes of death in modern society.1 These days, percutaneous coronary intervention (PCI) is the preferred reperfusion method of treatment of AMI compared to thrombolytic therapy due to the superior patency rates in the target coronary artery.2 Although the results for PCI in AMI are enough to achieve the desired patency of the target coronary artery, the major drawback is that the optimal perfusion is not achieved at the myocardial tissue level in some patients.3 These phenomenon, so called "no-reflow (NR)", leaves myocardial tissue hypoperfusion despite the restoration of epicardial coronary artery patency following PCI.4 There are several mechanisms that contribute to the development of NR, the main mechanism is thought to be the distal embolization of intracoronary thrombus.5 6 NR and distal embolization of intracoronary thrombus occur frequently during PCI and worsen clinical outcomes.7

NO-REFLOW AND DISTAL EMBOLIZATION OF INTRACORONARY THROMBUS

Through the past decade, PCI has been considered the standard treatment of AMI. Between 1999 and 2002, only 1/3 of patients with AMI who recieved reperfusion therapy underwent primary PCI in the National Registry of Myocardial Infarction (NRMI), with the remainder receiving thrombolytic therapy.8 However, in 2007, the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) registry reported nearly 90% of patients with AMI were treated using Primary PCI and only 4.3% using thrombolytic therapy.9 Now, primary PCI is the standard treatment of AMI in most of the hospitals that are able to provide it. The success of angiographic reperfusion by PCI is routinely evaluated by the Thrombolysis in Myocardial Infarction (TIMI) flow grade,10 myocardial blush scores11 12 and TIMI frame count.13 14 Despite high success rates of more than 95% for establishing epicardial artery patency after PCI,15 10 to 20 % of the patients leave the cath lab with reduced angiographical coronary flow(TIMI 0-2) descrbed as the no-reflow phenomenon(NR).5 16 17 NR may occur at any point during PCI. Usually NR is induced by inflations with balloons or coronary stents, which presumably lead to more distal embolization of coronary thrombus.18

NR was first described in 1974.19 The zone of NR was believed to be confined to areas of necrotic myocardium. It has been reported that myocardial cell death occurs before the disruption of the microvasculature.20 21 NR predicts worse outcome in animal models and post-infarct patients.22 23 A large zone of NR affects infarct healing, predicts infarct expansion and left ventricular dilatation.24 25 26 Failure to achieve the final TIMI 3 flow grades due to NR were reported in 20-40% of cases27 28, with in-hospital mortality rates from 12%,29 up to 40%.30 Reduced TIMI flow grades are also associated with increased infarct size, worsening of left ventricular function, arrhythmias and substantially increased mortality rates compared to patients with adequate TIMI 3 flow.31 32 Clinically, epicardial coronary flow shown by final coronary angiography after PCI has been considered to be an approximate surrogate for myocardial tissue perfusion. However, even in situations of restoration of normal TIMI-3 flow, marked reductions in myocardial tissue perfusion may be present.14

PATHOPHYSIOLOGY OF MYOCARDIAL INJURY RELATED TO NO-REFLOW BY INTRACORONARY THROMBUS

Myocardial ischemia occurs immediately after coronary artery occlusion, resulting in structural and metabolic derangements by oxygen-derived free radicals, degradation of sarcolemma, and calcium overload within the mitochondria and cytoplasm, which further degrade the cell membrane.33 Endothelial cell degradation, myocardial cell swelling and interstitial edema compress microvascular lumen and lead to tissue necrosis and cell death. Such ischemic cell death progresses from the subendocardial region towards the subepicardium.34 PCI to open the occluded epicardial coronary artery is crucial to prevent further progression of ischemic injury and salvage myocardium. However, the damage to the myocardium at the time of reperfusion by PCI has been controversial for many years.35 Infiltration of neutrophils and platelets into the coronary microcirculation at the time of reperfusion can obstruct the microcirculation.36 Activated neutrophils release oxygen free radicals, proteolytic enzymes and pro-inflammatory mediators that can cause tissue and endothelial damage, particularly in critically injured myocytes.37 Another mechanism for microvascular obstruction is the embolization of thrombus originating from unstable plaque during PCI. Using Doppler guidewires, multiple embolic particles were detected in patients who underwent PCI in an AMI setting.38 In a non-infarct model, embolization causing about 50% obstruction of coronary capillaries results in an irreversible reduction of myocardial blood flow.39 In animal models, distal coronary embolization produced severe regional contractile dysfunction, despite only 2-5% of minimal myocardial necrosis with leukocyte infiltration and preserved regional myocardial flow.40 In these microinfarcts, the contractile dysfunction following distal coronary embolization does appear to recover over time.41

After NR and microvascular plugging by embolization of intracoronary thrombus and ruptured plaque debris, microvascular integrity is compromised by cell swelling, interstitial edema, and capillary plugging by red blood cells, neutrophils and microthrombi, leading to progressively increased microcirculatory flow resistance.42 Also structural microvascular changes including tightly packed erythrocytes, platelets and fibrin thrombi occur and release vasoactive amines result in increased vascular tone and microvascular obstruction.19 This microvascular obstruction manifests in angiography after PCI with a slowing of contrast progression in the infarct-related artery. It leads to myocardial ischemia and necrosis at tissue level.8 20 Even angiographically successful reperfusion of the infarct-related artery does not guarantee adequate myocardial perfusion of the tissue levels, and the extent of microvascular obstruction correlate with infarct size and predicts worse outcome.43 44 45 About 20-30% of AMI patients with final TIMI3 flow after PCI demonstrated significant microvascular hypoperfusion by myocardial contrast echocardiography which is associated with functional deterioration.46

IMPACT OF NO-REFLOW AND DISTAL EMBOLIZATION OF INTRACORONARY THROMBUS

Distal embolization of intracoronary thrombus may have several worsening effects on myocardial infarct size and myocardial salvage strategies.22 47 During early stages of AMI, there is patchy necrosis with some intervening areas of viable cardiomyocytes at the infarct zone. Embolization of intracoronary thrombus in small vessels will be detrimental to the survival of these vulnerable myocytes. The infarct area extends beyond its borders by blocking the small arterioles and microvessels of the surrounding myocytes.21 Moreover, such NR and embolization of thrombus can prevent delivery of cardioprotective drugs to the myocytes in need. Consequently, distal embolization of intracoronary thrombus during PCI for AMI has been associated with inadequate tissue perfusion, poor reperfusion, larger infarct size and a more unfavorable prognosis.48 49

PREDICTORS OF NO-REFLOW AND DISTAL EMBOLIZATION OF THROMBUS

Thrombus burden at initial coronary angiography is a predictor of subsequent NR and distal embolization.50 High atheromatous burden, friability of the plaque and large lipid pool content are also known to contribute to NR in AMI patients undergoing PCI.50 Implanation of a stent to the thrombus-burdened coronary lesion is known to be another possible cause of NR and distal emblolization, presumably due to the stent mesh crushing plaque and squeezing particles through stent struts.18 51 In these lesions, distal embolization of thrombus was 3-fold higher after stenting in AMI compared to balloon inflations alone. Microemboli are frequently found in patients who died from ischemic heart disease and are associated with microinfarcts and an inflammatory reaction.52 MRI in post-MI patients demonstrates a higher incidence of perfusion defects after Primary PCI compared to thrombolysis, strongly suggesting procedure-related DCE.53 In current imaging studies, several grayscale IVUS features including greater plaque burden, plaque rupture, intracoronary thrombus, positive remodeling, and tissue prolapse predict NR in AMI patients.54 55 Also some virtual histology-IVUS features such as large necrotic core and thin-cap fibroatheroma were the independent predictors of NR in AMI patients.56 57

THERAPIES FOR THE NO-REFLOW AND DISTAL EMBOLIZATION OF INTRACORONARY THROMBUS

Recovery of intact microvasculature within the infarction zone leads to myocellular viability and potential functional recovery.45 Improved tissue perfusion to irreversibly damaged myocytes may have other benefits including prevention of infarct expansion or aneurysmal dilation and future development of collateral vessels.22 There have been some mixed results from studies focused on the prevention and treatment of NR and distal embolization of intracoronary thrombus.

1. Pharmacological approaches

NR also may prevent the delivery of pharmaceutical agents such as anti-arrhythmics and cardioprotectants into the infarct zone. In past small group studies, several agents have been shown to reduce and treat NR, including vasodilators, nitroprusside, calcium channel blockers, adenosine, nicorandil, and platelet glycoprotein IIb/IIIa inhibitors.58 59 60 61 62 63 64 65 66 67 68 69 70 71

Calcium channel blockers, such as verapamil and diltiazem, may have several potentially beneficial effects in the setting of no-reflow in addition to attenuation of microvascular spasms and reduction of myocardial ischemia and infarct size.61 62 Verapamil may inhibit platelet aggregation and thrombus formation in the microvasculature, and may have a direct effect on calcium flux across the sarcolemal membrane or within intracellular compartments that could protect injured myocytes.63

Adenosine affects intracellular calcium metabolism and inhibits neutrophil accumulation, superoxide generation, and intracellular acidification by affecting glucose utilization.64 65 In the AMISTAD and AMISTAD-II trials, intravenous adenosine treatment significantly reduced infarct size.66 67 Other studies report that administration of adenosine as an adjunct to primary angioplasty reduces the incidence of NR and improves ventricular function and clinical outcome.68 69

The ATP-sensitive potassium channel opening is known to be related to the development of the NR after PCI.70 Nicorandil, an ATP-dependent potassium channel opener, may prevent reperfusion injury and protects cardiac myocytes by blocking the mitochondrial permeability transition pore, reducing the influx of calcium, and inhibiting neutrophil accumulation and activation.71

Glycoprotein IIB/IIIA inhibitors have shown modest clinical benefit in the prevention of NR and intracoronary thrombus embolization from PCI for AMI.72 73 74 75 Some studies suggest that distal embolization sometimes reduces coronary blood flow only transiently, and is not associated with capillary obstruction.17 Despite the use of glycoprotein IIB/IIIA inhibitors and clot extraction devices, NR and abnormal myocardial perfusion based on myocardial blush scores still occur.76 Okamura reported 13% of patients had reduced TIMI-flow grades, despite routine use of clot extraction catheters and nicorandil to prevent R-NR.18 When these interventions fail, NR treatment is based on the intracoronary administration of adenosine, nicodandil or nipride to induce maximal vasodilation in small distal coronary vasculature.60 61 62 63 64 68 69 However, evidence of the beneficial effects of these agents on epicardial flow and myocardial salvage is still limited.

2. Device strategies for prevention of distal coronary embolization

Currently, clot extraction devices have shown modest clinical benefit resulting from PCI for AMI.77 78 79 However, disappointing results have been reported in two major trials (EMERALD, PROMISE) testing the use of filter devices to prevent DCE.78 80 Although the 100-micron pore size of the current filter devices may limit their effectiveness, the role of these filter devices on myocardial infarction is still questionable.

On the other hand, the thrombus burden has been thought to be a major cause of some of these adverse outcomes, so thrombus aspiration, at least macroscopically visible thrombi, is assumed to improve clinical outcome. Furthermore, the additional benefit of clot extraction by aspiration may be not only the removal of the thrombus but also vasoactive and chemotactic mediators released from platelets that may exacerbate tissue injury. On the basis of this assumption, mechanical thrombectomy and manual thrombus aspiration devices were evaluated, but showed little or no effect on clinical endpoints.81 The major breakthrough came with the TAPAS (Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study) trial, which was a single-center, randomized, all-comer trial of routine thrombus aspiration versus conventional PCI.82 The trial enrolled 1,071 patients, with thrombus aspiration being performed in 89% in the active arm and in 1% in the control arm. This TAPAS trial was positive not only with respect to the primary endpoint but also mortality at 1 year.

In two recent, large randomized trials, the Thrombus Aspiration in STElevation Myocardial Infarction in Scandinavia (TASTE)83 and A Randomized Trial of Routine Aspiration ThrOmbecTomy with PCI Versus PCI alone in Patients With STEMI Undergoing Primary PCI (TOTAL) trial84 reported different conclusions compared with the TAPAS trial. These trials were prospective, randomized, multicenter studies of 7,244 and 10,732 AMI patients with thrombus aspiration group or conventional PCI alone group, respectively. The results of both trials were negative including both the primary and secondary endpoints. Also, some disappointing findings wer reported in the TOTAL trial as the stroke rates increased in the thrombus aspiration group.85 In the results of the trials, it seems that there may be no clinical benefit to routine thrombus aspiration in patients with STEMI during PCI. However, the TASTE trial had shown that there was no clinical benefit from aspiration, whilst TOTAL had gone further confirming that aspiration does not provide benefits and in fact appears to cause harm. There may be several reasons for the different results between the TASTE and TOTAL trials relative to the TAPAS trial. Compared with the TAPAS trial, the TASTE and TOTAL trials included a lower risk population with a possibility of selection bias, fewer glycoprotein IIB/IIIA inhibitors were used in the aspiration arm in TOTAL trial and only 4.9% in TASTE and 7.1% in patients of TOTAL trial underwent bail-out thrombus aspiration. Therefore, a selection bias may be responsible for the lack of benefit in these two studies, despite the statistical analysis. Consequently, aspiration techniques may not be sufficient to remove the thrombus safely in patients with a high risk of microembolization. Lastly, although TAPAS was successful, it was still a single-center study, so extended to multicenter studies will be needed. It may be hard to draw any definite conclusions because the registry studies do not specify which patients were chosen for the thrombus aspiration, whether subjects were selected on the basis of TIMI flow grade, thrombus burden, time from PCI, or other criteria. Interestingly, another large, recent British registry study conflicted with the TASTE and TOTAL studies, by showing significant reduction of in-hospital and long term mortality in patients who underwent thrombus aspiration.86

Large randomized controlled registry studies thus show conflicting results of thrombus aspiration as a routine treatment in STEMI during PCI. However, most trials now find that there is no clinical benefit of routine thrombus aspiration in the treatment of STEMI patients.

The question remains as to whether the results from recent trials mean that there is no benefit of using thrombus aspiration in selected high-risk patients.

SUMMARY

Coronary NR and distal embolization of intracoronary thrombus is a common complication of PCI which may severely compromise procedural outcomes. NR has a complex pathophysiology which relates to the patient's clinical and angiographic characteristics as well as PCI procedure. Preventive and treatment strategies have shown mixed results and the value of interventions such as distal protection or thrombus aspiration is still unclear. Further development of drugs and devices may lead to improved procedural outcomes in the future.

Notes

^{CONFLICT OF INTEREST STATEMENT} None declared.

References

1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004; 110:e82–e292.

2. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006; 113:e166–e286.

3. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol. 2000; 85:50B–60B.

4. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001; 22:729–739.

5. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008; 117:3152–3156.

6. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000; 101:570–580.

7. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000; 36:1202–1209.

8. McNamara RL, Herrin J, Bradley EH, Portnay EL, Curtis JP, Wang Y, et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol. 2006; 47:45–51.

9. Diercks DB, Kontos MC, Chen AY, Pollack CV Jr, Wiviott SD, Rumsfeld JS, et al. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009; 53:161–166.

10. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985; 312:932–936.

11. Bellandi F, Leoncini M, Maioli M, Toso A, Gallopin M, Piero Dabizzi R. Markers of myocardial reperfusion as predictors of left ventricular function recovery in acute myocardial infarction treated with primary angioplasty. Clin Cardiol. 2004; 27:683–688.

12. Vicente J, Mewton N, Croisille P, Staat P, Bonnefoy-Cudraz E, Ovize M, et al. Comparison of the angiographic myocardial blush grade with delayed-enhanced cardiac magnetic resonance for the assessment of microvascular obstruction in acute myocardial infarctions. Catheter Cardiovasc Interv. 2009; 74:1000–1007.

13. Evola S, Cuttitta F, Evola G, Macaione F, Piraino D, Meschisi MC, et al. Early detection of coronary artery flow and myocardial perfusion impairment in hypertensive patients evidenced by myocardial blush grade (MBG) and thrombolysis in myocardial infarction (TIMI) frame count (TFC). Intern Med. 2012; 51:1653–1660.

14. Lee CH, Tai BC, Lau C, Chen Z, Low AF, Teo SG, et al. Relation between door-to-balloon time and microvascular perfusion as evaluated by myocardial blush grade, corrected TIMI frame count, and ST-segment resolution in treatment of acute myocardial infarction. J Interv Cardiol. 2009; 22:437–443.

15. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999; 341:1949–1956.

16. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992; 85:1699–1705.

17. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996; 93:1993–1999.

18. Okamura A, Ito H, Iwakura K, Kurotobi T, Koyama Y, Date M, et al. Clinical implications of distal embolization during coronary interventional procedures in patients with acute myocardial infarction: quantitative study with Doppler guidewire. JACC Cardiovasc Interv. 2008; 1:268–276.

19. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974; 54:1496–1508.

20. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1980; 62:945–952.

21. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2002; 282:H766–H772.

22. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? Am J Physiol Heart Circ Physiol. 2003; 284:H1134–H1141.

23. Kenner MD, Zajac EJ, Kondos GT, Dave R, Winkelmann JW, Joftus J, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. Am J Cardiol. 1995; 76:861–868.

24. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009; 54:281–292.

25. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008; 72:950–957.

26. Reffelmann T, Hale SL, Dow JS, Kloner RA. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation. 2003; 108:2911–2917.

27. Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O'Neill W, et al. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol. 2003; 92:1445–1447.

28. Ross AM, Lundergan CF, Rohrbeck SC, Boyle DH, van den, Buller CH, et al. Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1998; 31:1511–1517.

29. Patel TN, Bavry AA, Kumbhani DJ, Ellis SG. A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis. Am J Cardiol. 2006; 97:1685–1690.

30. Sutton AG, Campbell PG, Price DJ, Grech ED, Hall JA, Davies A, et al. Failure of thrombolysis by streptokinase: detection with a simple electrocardiographic method. Heart. 2000; 84:149–156.

31. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995; 130:239–243.

32. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996; 93:223–228.

33. Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol. 1981; 13:229–239.

34. Engler RL, Freeman GL, Covell JW. Regional venous return: nitroprusside effect in normal and chronically congested dogs. Am J Physiol. 1983; 245:H814–H823.

35. Nayler WG, Elz JS. Reperfusion injury: laboratory artifact or clinical dilemma? Circulation. 1986; 74:215–221.

36. Chiariello M, Ambrosio G, Cappelli-Bigazzi M, Perrone-Filardi P, Tritto I, Nevola E, et al. Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. Am Heart J. 1990; 120:801–807.

37. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005; 100:179–190.

38. Okamura A, Ito H, Iwakura K, Kawano S, Inoue K, Maekawa Y, et al. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device. J Am Coll Cardiol. 2005; 45:212–215.

39. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J, et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol. 1986; 250:H509–H518.

40. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am J Physiol Heart Circ Physiol. 2002; 282:H611–H614.

41. Skyschally A, Haude M, Dörge H, Thielmann M, Duschin A, van de Sand A, et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation. 2004; 109:2337–2342.

42. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart. 2002; 87:162–168.

43. Tarantini G, Cacciavillani L, Corbetti F, Ramondo A, Marra MP, Bacchiega E, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol. 2005; 46:1229–1235.

44. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998; 97:765–772.

45. Ragosta M, Camarano G, Kaul S, Powers ER, Sarembock IJ, Gimple LW. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography. Circulation. 1994; 89:2562–2569.

46. Galasso G, Schiekofer S, D'Anna C, Gioia GD, Piccolo R, Niglio T, et al. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology. 2014; 65:180–189.

47. Kotani J, Mintz GS, Pregowski J, Kalinczuk L, Pichard AD, Satler LF, et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol. 2003; 92:728–732.

48. Kenner MD, Zajac EJ, Kondos GT, Dave R, Winkelmann JW, Joftus J, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. Am J Cardiol. 1995; 76:861–868.

49. Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van't Hof AW, Hoorntje JC, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002; 23:1112–1117.

50. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, Fang CY, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002; 122:1322–1332.

51. Tanaka A, Kawarabayashi T, Nishibori Y, Sano T, Nishida Y, Fukuda D, et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation. 2002; 105:2148–2152.

52. Heusch G, Schulz R, Haude M, Erbel R. Coronary microembolization. J Mol Cell Cardiol. 2004; 37:23–31.

53. Motoyama S, Kondo T, Anno H, Kizukuri T, Nakamura Y, Oshima K, et al. Relationship between thrombolytic therapy and perfusion defect detected by Gd-DTPA-enhanced fast magnetic resonance imaging in acute myocardial infarction. J Cardiovasc Magn Reson. 2001; 3:237–245.

54. Hong YJ, Jeong MH, Ahn Y, Kang JC, Mintz GS, Kim SW, et al. Intravascular ultrasound findings that are predictive of no reflow after percutaneous coronary intervention for saphenous vein graft disease. Am J Cardiol. 2012; 109:1576–1581.

55. Katayama T, Kubo N, Takagi Y, Funayama H, Ikeda N, Ishida T, et al. Relation of atherothrombosis burden and volume detected by intravascular ultrasound to angiographic no-reflow phenomenon during stent implantation in patients with acute myocardial infarction. Am J Cardiol. 2006; 97:301–304.

56. Amano H, Wagatsuma K, Yamazaki J, Ikeda T. Virtual histology intravascular ultrasound analysis of attenuated plaque and ulcerated plaque detected by gray scale intravascular ultrasound and the relation between the plaque composition and slow flow/no reflow phenomenon during percutaneous coronary intervention. J Interv Cardiol. 2013; 26:295–301.

57. Sakata K, Kawashiri MA, Ino H, Matsubara T, Uno Y, Yasuda T, et al. Intravascular ultrasound appearance of scattered necrotic core as an index for deterioration of coronary flow during intervention in acute coronary syndrome. Heart Vessels. 2012; 27:443–452.

58. Fischell TA. Pharmaceutical interventions for the management of no-reflow. J Invasive Cardiol. 2008; 20:374–379.

59. Harding SA. The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention. Heart. 2006; 92:1191–1193.

60. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005; 95:1358–1361.

61. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol. 2000; 12:80–85.

62. McIvor ME, Undemir C, Lawson J, Reddinger J. Clinical effects and utility of intracoronary diltiazem. Cathet Cardiovasc Diagn. 1995; 35:287–291.

63. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997; 30:1193–1199.

64. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000; 101:2154–2159.

65. Nolte D, Lehr HA, Messmer K. Adenosine inhibits postischemic leukocyte-endothelium interaction in postcapillary venules of the hamster. Am J Physiol. 1991; 261:H651–H655.

66. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999; 34:1711–1720.

67. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005; 45:1775–1780.

68. Lim SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J. 2004; 68:928–932.

69. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv. 2000; 51:27–31.

70. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol. 2002; 40:1339–1346.

71. Louis AA, Manousos IR, Coletta AP, Clark AL, Cleland JG. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. Eur J Heart Fail. 2002; 4:111–116.

72. Kloner RA, Dai W. Glycoprotein IIb/IIIa inhibitors and no-reflow. J Am Coll Cardiol. 2004; 43:284–286.

73. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004; 43:276–283.

74. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344:1895–1903.

75. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004; 147:457–462.

76. De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J. 2008; 29:3002–3010.

77. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008; 29:2989–3001.

78. Gick M, Jander N, Bestehorn HP, Kienzle RP, Ferenc M, Werner K, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation. 2005; 112:1462–1469.

79. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008; 358:557–567.

80. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005; 293:1063–1072.

81. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008; 29:2989–3001.

82. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008; 371:1915–1920.

83. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013; 369:1587–1597.

84. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015; 372:1389–1398.

85. Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med. 2014; 371:1111–1120.

86. Noman A, Egred M, Bagnall A, Spyridopoulos I, Jamieson S, Ahmed J. Impact of thrombus aspiration during primary percutaneous coronary intervention on mortality in ST-segment elevation myocardial infarction. Eur Heart J. 2012; 33:3054–3061.

TOOLS

Similar articles